PubMed · 16044668
Talnetant GlaxoSmithKline.
Abstract
Talnetant (SB-223412) is a selective, orally active NK3 antagonist based on 4-quinolinecarboxamide, and is under development by GlaxoSmithKline (formerly SmithKline Beecham) for the potential treatment of several disorders, including urinary incontinence, irritable bowel syndrome and schizophrenia. By November 2004, the compound had completed phase II trials.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Stefano Evangelista. 2005. Talnetant GlaxoSmithKline.. https://pubmed.ncbi.nlm.nih.gov/16044668/
Cite the original work for its findings. Save a collection to share your selection of sources.